keyword
MENU ▼
Read by QxMD icon Read
search

Bisphosphonate

keyword
https://www.readbyqxmd.com/read/28339664/adult-paget-s-disease-of-bone-a-review
#1
Stephen Paul Tuck, Robert Layfield, Julie Walker, Babitha Mekkayil, Roger Francis
Adult PD of bone is the second commonest metabolic bone condition after osteoporosis. The condition is characterized by increased bone cell activity, with bone-resorbing osteoclasts often larger and containing more nuclei than normal, and osteoblasts producing increased amounts of disorganized bone. This leads to expanded bone of poor quality possessing both sclerotic and lytic areas. PD of bone has a strong genetic element, with a family history being noted in 10-20% of cases. A number of genetic defects have been found to be associated with the condition...
February 17, 2017: Rheumatology
https://www.readbyqxmd.com/read/28338455/long-term-administration-of-bisphosphonate-to-reduce-local-recurrence-of-sacral-giant-cell-tumor-after-nerve-sparing-surgery
#2
Wei Xu, Yu Wang, Jing Wang, Xinghai Yang, Weibo Liu, Wang Zhou, Tielong Liu, Jianru Xiao
OBJECTIVE The objective of this study was to investigate the effect of long-term bisphosphonate treatment on reducing local recurrence of sacral giant cell tumors (GCTs) after nerve-sparing surgery. METHODS Thirty-five consecutive patients with sacral GCTs who received treatment in Shanghai Changzheng Hospital between January 2000 and December 2010 were included in this study. Between January 2007 and December 2010, 19 patients received bisphosphonates following nerve-sparing surgery. Before January 2007, 16 patients received nerve-sparing surgery alone, and these cases were included as the control group...
March 24, 2017: Journal of Neurosurgery. Spine
https://www.readbyqxmd.com/read/28337806/the-pharmacological-profile-of-a-novel-highly-potent-bisphosphonate-ox14-1-fluoro-2-imidazo-1-2-%C3%AE-pyridin-3-yl-ethyl-bisphosphonate
#3
M A Lawson, F H Ebetino, A Mazur, A D Chantry, J Paton-Hough, H R Evans, D Lath, M K Tsoumpra, M W Lundy, R L M Dobson, M Quijano, A A Kwaasi, J E Dunford, X Duan, J T Triffitt, G Jeans, R G G Russell
Bisphosphonates are widely used in the treatment of clinical disorders characterized by increased bone resorption, including osteoporosis, Paget's disease and the skeletal complications of malignancy. The anti-resorptive potency of the nitrogen-containing bisphosphonates on bone in vivo is now recognised to depend upon two key properties, namely mineral binding affinity and inhibitory activity on farnesyl pyrophosphate synthase (FPPS), and these properties vary independently of each other in individual bisphosphonates...
March 24, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28337514/effect-of-sequential-treatment-with-bisphosphonates-after-teriparatide-in-ovariectomized-rats-a-direct-comparison-between-risedronate-and-alendronate
#4
Tetsuo Yano, Mei Yamada, Daisuke Inoue
Teriparatide (TPTD), a recombinant human parathyroid hormone N-terminal fragment (1-34), is a widely used bone anabolic drug for osteoporosis. Sequential treatment with antiresorptives such as bisphosphonates after TPTD discontinuation is generally recommended. However, relative effects of bisphosphonates have not been determined. In the present study, we directly compared effects of risedronate (RIS) and alendronate (ALN) on bone mineral density (BMD), bone turnover, structural property and strength in ovariectomized (OVX) rats, when administered after TPTD...
March 23, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/28336832/-surgical-and-non-surgical-management-of-primary-hyperparathyroidism-how-do-calcimimetics-work
#5
Yasuhiro Takeuchi
Primary hyperparathyroidism is a common endocrine disease. The first line therapy for the disease is surgical removal of affected parathyroid gland(s). Other therapeutic options with medication are needed to be established, because many of patients with primary hyperparathyroidism have few or no symptoms and are expected to have a long life expectancy without surgery. Cinacalcet as a calcimimetic, bisphosphonates and denosumab are promising candidates for medical management of the disease. Effectiveness and efficiency of these drugs for patients with primary hyperparathyroidism is to be evaluated in comparison with surgical treatment...
2017: Clinical Calcium
https://www.readbyqxmd.com/read/28334435/withdrawn-radioisotopes-for-metastatic-bone-pain
#6
REVIEW
Marta Roqué I Figuls, Maria José Martinez-Zapata, Martin Scott-Brown, Pablo Alonso-Coello
BACKGROUND: This is an update of the review published in Issue 4, 2003. Bone metastasis cause severe pain as well as pathological fractures, hypercalcaemia and spinal cord compression. Treatment strategies currently available to relieve pain from bone metastases include analgesia, radiotherapy, surgery, chemotherapy, hormone therapy, radioisotopes and bisphosphonates. OBJECTIVES: To determine efficacy and safety of radioisotopes in patients with bone metastases to improve metastatic pain, decrease number of complications due to bone metastases and improve patient survival...
March 23, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28332833/uranyl-peroxide-clusters-incorporating-iron-trimers-and-bridging-by-bisphosphonate-and-carboxylate-containing-ligands
#7
Jie Qiu, Sining Dong, Jennifer E S Szymanowski, Malgorzata Dobrowolska, Peter C Burns
A hybrid uranium-iron cage nanocluster, [(UO2)24(FeOH)24(O2)24(PO4)8(CH(COO)(PO3)2)24](96-) (U24Fe24), was synthesized using bridging ligands containing bisphosphonate and carboxylate groups. U24Fe24 contains six tetramers of uranyl hexagonal bipyramids and eight iron trimers, each of which consists of three corner-sharing Fe(3+) octahedra and is stabilized by in situ formed phosphate and 2,2-bis(phosphonato)acetate (C2P2) groups. Tetramers and trimers are bridged by 24 C2P2 groups into a cage cluster. Crystals of U24Fe24 present a paramagnetic-like behavior...
March 23, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28330568/-evaluation-of-healing-time-of-osteochemonecrosis-of-the-jaw-after-surgery-single-center-retrospective-study-and-review-of-the-literature
#8
A Berquet, A Louvrier, F Denis, F Bornert, E Weber, C Meyer
INTRODUCTION: Osteochemonecrosis of the jaw (ONJ) is a chronic ischemic bone exposure. It has an increasing incidence. ONJ is mainly related to bisphosphonate and denosumab therapies in oncologic settings. Healing is considered uncertain ad as occurring slowly. International recommendations suggest to treat ONJ symptomatically in a first attempt. A surgical procedure, potentially aggressive, should be carefully weight up in patients in poor condition and whose life expectancy is often limited...
February 2017: J Stomatol Oral Maxillofac Surg
https://www.readbyqxmd.com/read/28328803/incident-acute-pseudogout-and-prior-bisphosphonate-use-matched-case-control-study-in-the-uk-clinical-practice-research-datalink
#9
Edward Roddy, Sara Muller, Zoe Paskins, Samantha L Hider, Milisa Blagojevic-Bucknall, Christian D Mallen
Oral bisphosphonates are the most commonly used drugs to treat postmenopausal osteoporosis. Acute pseudogout is anecdotally reported to occur following bisphosphonate initiation but empirical data are lacking. We investigated whether treatment with oral bisphosphonates is a risk factor for incident acute pseudogout.A matched case-control study was undertaken using data from the UK-Clinical Practice Research Datalink. Adults who consulted for incident acute pseudogout between 1987 and 2012 were each matched for gender, age at pseudogout diagnosis, and general practice to up to 4 control subjects without pseudogout...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28326724/-research-progress-on-bisphosphonate-related-osteonecrosis-of-the-jaws
#10
Pan Jian, Wang Qizhang, Liu Jiyuan
Bisphosphonates (BPs), as potent drugs inhibiting bone resorption, have been widely used for treatment of several diseases. In recent years, dentists and oral and maxillofacial surgeons reported continuously increasing cases of bisphosphonate-related osteonecrosis of the jaws (BRONJ). This disease is clinically characterized by exposed bones, formation of sequestrum, pain, and halitosis. Provided that pathogenesis of BRONJ is unclear, effective treatments for this disease are currently unavailable. Thus, prevention plays an important role in the management of BRONJ...
February 1, 2017: Hua Xi Kou Qiang Yi Xue za Zhi, Huaxi Kouqiang Yixue Zazhi, West China Journal of Stomatology
https://www.readbyqxmd.com/read/28326420/proximal-femoral-reconstruction-for-failed-internal-fixation-of-a-bisphosphonate-related-femur-fracture
#11
Rishabh G Jethanandani, Chima Nwankwo, Philip R Wolinsky, Mauro Giordani, Derek F Amanatullah
We present a case of a bisphosphonate-related femur fracture in an elderly woman, who failed treatment with both cephalomedullary nail and proximal femoral locking plate, leading to successful treatment with total hip arthroplasty. Hardware failure should be included in the differential of patients with previous internal fixation of bisphosphonate-related femur fracture that present with hip or groin pain. Arthroplasty can be an acceptable salvage option in an active elderly patient with a bisphosphonate-related femur fracture...
December 2016: Arthroplasty Today
https://www.readbyqxmd.com/read/28326419/bilateral-atypical-femoral-fracture-and-end-stage-arthritis-of-the-hip-treated-with-total-hip-arthroplasty
#12
Scott M Sandilands, Jesus M Villa, Carlos J Lavernia
The prolonged use of bisphosphonates has been associated with an increased rate of atypical femoral fracture. A 77-year-old woman with prolonged bisphosphonate use presented to our office with groin pain and end-stage arthritis, She was scheduled for a total hip replacement. Before the surgery and with minimal trauma, the patient then suffered a displaced atypical femoral fracture. She underwent a total hip replacement as a treatment for her fracture and her arthritis. Subsequently, the patient presented with pain in the contralateral thigh with an incomplete atypical femoral fracture...
December 2016: Arthroplasty Today
https://www.readbyqxmd.com/read/28326338/predictors-of-teriparatide-treatment-failure-in-patients-with-low-bone-mass
#13
Tarig Elraiyah, Adil H Ahmed, Zhen Wang, Joshua N Farr, Mohammad H Murad, Matthew T Drake
INTRODUCTION: While teriparatide is the only skeletal anabolic agent approved in the United States, treatment failure is a major concern which complicates its clinical utility. We sought to identify factors that predict response failure in patients with low bone mass. METHOD: We performed a retrospective study of adults with osteopenia or osteoporosis (T-scores < - 1.0 and - 2.5 SD below normal, respectively, at the total hip or lumbar spine) treated with teriparatide at the Mayo Clinic (Rochester, Minnesota) between November 2002-December 2012...
June 2016: Bone Reports
https://www.readbyqxmd.com/read/28326336/association-between-gastrointestinal-events-and-compliance-with-osteoporosis-therapy
#14
Ethel S Siris, Chun-Po Steve Fan, Xiaoqin Yang, Shiva Sajjan, Shuvayu S Sen, Ankita Modi
PURPOSE: The aim of this study was to estimate the rate of gastrointestinal (GI) events, and association between GI events and compliance with osteoporosis therapy among osteoporotic women. METHODS: A retrospective cohort study using a large administrative claims database in the United States from 2001 through 2010 was conducted. We studied women ≥ 55 years old who were continuously enrolled in a health plan for at least 2 years, a baseline year before and a follow-up year after the date of the first prescription of oral bisphosphonate as the first oral osteoporosis treatment...
June 2016: Bone Reports
https://www.readbyqxmd.com/read/28326300/the-efficacy-of-bisphosphonates-for-prevention-of-osteoporotic-fracture-an-update-meta-analysis
#15
Ji-Hye Byun, Sunmee Jang, Sumin Lee, Suyeon Park, Hyun Koo Yoon, Byung-Ho Yoon, Yong-Chan Ha
BACKGROUND: The efficacy of bisphosphonates for osteoporotic fracture has been consistently reported in recent randomized controlled trials (RCTs) enrolling hundreds of patients. The objective of this study was to update knowledge on the efficacy of available bisphosphonates in the prevention of vertebral and non-vertebral fractures. METHODS: An approach "using systematic reviews" on PubMed and Cochrane Library was taken. Twenty-four RCTs investigating the effects of bisphosphonates for the prevention of osteoporotic fracture were included in final analysis...
February 2017: Journal of Bone Metabolism
https://www.readbyqxmd.com/read/28325144/therapeutic-potential-and-outlook-of-alternative-medicine-for-osteoporosis
#16
Tao Wang, Qian Liu, William Tjhioe, Jinmin Zhao, Aiping Lu, Ge Zhang, Renxiang Tan, Mengyu Zhou, Jiake Xu, Haotian Feng
Osteoporosis, a bone disease resulting in loss of bone density and microstructure quality, is often associated with fragility fractures, and the latter imposes a great burden on the patient and society. Although there are several different treatments available for osteoporosis such as hormone replacement therapy, bisphosphonates, Denosumab, and parathyroid hormone some concern has been raised regarding the inherent side effects of their long term use. It would be of great relevance to search for alternative natural compounds, which could complementarily overcome the limitations of the currently available therapy...
March 21, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28323993/bisphosphonate-treatment-and-the-characteristics-of-femoral-fractures-in-children-with-osteogenesis-imperfecta
#17
Ilkka Vuorimies, Mervi K Mäyränpää, Helena Valta, Heikki Kröger, Sanna Toiviainen-Salo, Outi Mäkitie
CONTEXT: Bisphosphonates' (BPs) short-term benefits are evident in the treatment of children with osteogenesis imperfecta (OI) but some concerns related to long-term effects still remain. OBJECTIVE: To elucidate the effect of BPs on characteristics of femoral fractures in children with OI. DESIGN AND SETTING: Retrospective cohort study at a university hospital. PATIENTS AND MAIN OUTCOME MEASURE: Study included 93 patients with OI...
January 17, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28323974/phenotypic-spectrum-in-osteogenesis-imperfecta-due-to-mutations-in-tmem38b-unravelling-a-complex-cellular-defect
#18
Emma A Webb, Meena Balasubramanian, Nadja Fratzl-Zelman, Wayne A Cabral, Hannah Titheradge, Atif Alsaedi, Vrinda Saraff, Julie Vogt, Trevor Cole, Susan Stewart, Nicola J Crabtree, Brandi M Sargent, Sonja Gamsjaeger, Eleftherios P Paschalis, Paul Roschger, Klaus Klaushofer, Nick J Shaw, Joan C Marini, Wolfgang Högler
Context: Recessive mutations in TMEM38B cause type XIV osteogenesis imperfecta (OI) by dysregulating intracellular calcium flux. Objectives: Clinical and bone material phenotype description and osteoblast differentiation studies. Design and Setting: Natural history study in paediatric research centres. Patients: Eight patients with type XIV OI. Main Outcome Measures: Clinical examinations included: bone mineral density, radiographs, echocardiography and muscle biopsy...
March 16, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28323714/osteointegration-and-resorption-of-intravertebral-and-extravertebral-calcium-phosphate-cement
#19
Roman Klein, Ralf Tetzlaff, Christel Weiss, Meike-Kristina Schäfer, Michael Tanner, Bernd Wiedenhöfer, Ingo Grafe, Peter-Jürgen Meeder, Gerd Noeldge, Peter P Nawroth, Christian Kasperk
STUDY DESIGN: Eleven patients with painful osteoporotic vertebral fractures who underwent kyphoplasty using calcium phosphate (CaP) cement were followed up for 1 week, 1, 2, and 3 years in a monocentric, nonrandomized, noncontrolled retrospective trial. OBJECTIVE: This study investigates long-term radiomorphologic features of intraosseous CaP cement implants and of extraosseous CaP cement leakages for up to 3 years after implantation by kyphoplasty. SUMMARY OF BACKGROUND DATA: Kyphoplasty is frequently used for the treatment of painful osteoporotic fractures...
April 2017: Clinical Spine Surgery
https://www.readbyqxmd.com/read/28323142/zoledronic-acid-improves-bone-histomorphometry-in-a-murine-model-of-rett-syndrome
#20
Jay R Shapiro, Adele L Boskey, Stephen B Doty, Lyudmila Lukashova, Mary E Blue
Rett syndrome (RTT) is a neurodevelopmental disorder predominately affecting young females, caused by deficiency of the global transcriptional protein methyl CpG binding protein 2 (MeCP2). Osteoblasts express MeCP2 and girls with RTT experience early onset osteoporosis, decreased bone mass and an increased fracture risk. There is no defined treatment for osteoporosis associated with RTT. The present study evaluated the effects of zoledronic acid (ZA), a third generation nitrogen-containing bisphosphonate with primarily anti-osteoclastic activity, in a mouse model of MeCP2 deficiency...
March 18, 2017: Bone
keyword
keyword
49305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"